Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Revenue: 2022-2025

Historic Revenue for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $171.0 million.

  • Axsome Therapeutics' Revenue rose 63.22% to $171.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $561.3 million, marking a year-over-year increase of 65.83%. This contributed to the annual value of $385.7 million for FY2024, which is 42.53% up from last year.
  • Axsome Therapeutics' Revenue amounted to $171.0 million in Q3 2025, which was up 13.96% from $150.0 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Revenue registered a high of $171.0 million during Q3 2025, and its lowest value of $16.8 million during Q3 2022.
  • In the last 3 years, Axsome Therapeutics' Revenue had a median value of $94.6 million in 2023 and averaged $99.9 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 243.07% in 2023, then dropped by 20.70% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Revenue (Quarterly) stood at $24.4 million in 2022, then skyrocketed by 193.50% to $71.5 million in 2023, then soared by 66.04% to $118.8 million in 2024, then soared by 63.22% to $171.0 million in 2025.
  • Its Revenue stands at $171.0 million for Q3 2025, versus $150.0 million for Q2 2025 and $121.5 million for Q1 2025.